Latest Advances in Lung Cancer Research

Patients with pretreated SCLC have improved outcomes. Apatinib combined with chemotherapy in patients with prior treatments indicate good efficacy/safety.

IASLC discusses lung cancer care and research disparities among socioeconomic, ethnic, racial, and gender-related groups.

Tepotinib approved for MET+ NSCLC treatment. Specifically, approval for metastatic NSCLC with MET exon 14 skipping alterations.

Breast cancer tops lung cancer as most diagnosed cancer. Although breast cancer leads in cases, lung cancer leads in deaths.

Why are lung cancer deaths in non-smokers on the rise? The proportion of non-smoker lung cancer patients jumped from 8% in 1990 to 15% in 2013.

Merck pulls Keytruda for SCLC. Pharmaceutical company, Merck announced plans to pull Ketruda for SCLC due to disappointing results from Phase III trial.

Antibody hinders EGFR lung cancer: Johnson&Johnson’s drug shows succes in hindering tumor growth in 74% of lung cancer patients with EGFR mutations.

Study defines SCLC subtypes. Study provides a transformative new system to define four major groups of small-cell lung cancer.

How biomarkers impact treatment decisions. Biomarkers indicate that a patient’s immune system knows that the tumor is there.

Genetics influence SCLC risk: The genetic factors that influence small cell lung cancer risk have not received a great deal of attention from scientists.

Exploring saliva in early lung cancer detection: UCLA School of Dentistry researchers are looking at saliva for its diagnostic possibilities.

A sizable body of research has long shown racial disparities in treatment and survival between Black and White patients with lung cancer.